TWST Strangle Strategy
TWST (Twist Bioscience Corporation), in the Healthcare sector, (Medical - Diagnostics & Research industry), listed on NASDAQ.
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
TWST (Twist Bioscience Corporation) trades in the Healthcare sector, specifically Medical - Diagnostics & Research, with a market capitalization of approximately $6.22B, a beta of 2.21 versus the broader market, a 52-week range of 23.3-104.23, average daily share volume of 1.6M, a public-listing history dating back to 2018, approximately 923 full-time employees. These structural characteristics shape how TWST stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 2.21 indicates TWST has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a strangle on TWST?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current TWST snapshot
As of June 30, 2026, spot at $100.66, ATM IV 81.30%, IV rank 32.91%, expected move 23.31%. The strangle on TWST below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this strangle structure on TWST specifically: TWST IV at 81.30% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 23.31% (roughly $23.46 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated TWST expiries trade a higher absolute premium for lower per-day decay. Position sizing on TWST should anchor to the underlying notional of $100.66 per share and to the trader's directional view on TWST stock.
TWST strangle setup
The TWST strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With TWST near $100.66, the first option leg uses a $105.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed TWST chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 TWST shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $105.00 | $5.25 |
| Buy 1 | Put | $95.00 | $5.00 |
TWST strangle risk and reward
- Net Premium / Debit
- -$1,025.00
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$1,025.00
- Breakeven(s)
- $84.75, $115.25
- Risk / Reward Ratio
- Unbounded
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
TWST strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on TWST. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | +$8,474.00 |
| $22.27 | -77.9% | +$6,248.46 |
| $44.52 | -55.8% | +$4,022.92 |
| $66.78 | -33.7% | +$1,797.39 |
| $89.03 | -11.6% | -$428.15 |
| $111.29 | +10.6% | -$396.31 |
| $133.54 | +32.7% | +$1,829.23 |
| $155.80 | +54.8% | +$4,054.76 |
| $178.05 | +76.9% | +$6,280.30 |
| $200.31 | +99.0% | +$8,505.84 |
When traders use strangle on TWST
Strangles on TWST are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the TWST chain.
TWST thesis for this strangle
The market-implied 1-standard-deviation range for TWST extends from approximately $77.20 on the downside to $124.12 on the upside. A TWST long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current TWST IV rank near 32.91% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on TWST should anchor more to the directional view and the expected-move geometry. As a Healthcare name, TWST options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to TWST-specific events.
TWST strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. TWST positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move TWST alongside the broader basket even when TWST-specific fundamentals are unchanged. Always rebuild the position from current TWST chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on TWST?
- A strangle on TWST is the strangle strategy applied to TWST (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With TWST stock trading near $100.66, the strikes shown on this page are snapped to the nearest listed TWST chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are TWST strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the TWST strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 81.30%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$1,025.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a TWST strangle?
- The breakeven for the TWST strangle priced on this page is roughly $84.75 and $115.25 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current TWST market-implied 1-standard-deviation expected move is approximately 23.31%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on TWST?
- Strangles on TWST are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the TWST chain.
- How does current TWST implied volatility affect this strangle?
- TWST ATM IV is at 81.30% with IV rank near 32.91%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.